


# COVID-19 Vaccine Brand Guidance for Clinicians

The purpose of this document is to assist clinicians and vaccine providers in determining patient vaccine eligibility.



## Please note:

- 1) People who have had their first dose of the AstraZeneca vaccine without any serious adverse events can be given their second dose – this includes adults under 50 years of age. A severe adverse event is thrombosis with thrombocytopenia syndrome (TTS) or anaphylaxis to Polysorbate 80 or a previous dose of the AstraZeneca vaccine.
- 2) If vaccinee is **<50 years** old and **has a contraindication to the Pfizer vaccine as above**, please refer to the Victorian Specialist Immunisation Services (VicSIS) network using the VicSIS referral form found here: <https://mvec.mcri.edu.au/references/the-vicsis-victorian-specialist-immunisation-services-network/>
- 3) COVID-19 Vaccine AstraZeneca can be used in adults aged under 50 years where the benefits are likely to outweigh the risks for that individual and the person has made an informed decision based on an understanding of the risks and benefits.